FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016647821> ?p ?o ?g. }

• W3016647821 endingPage "3" @default.
• W3016647821 startingPage "1" @default.
• W3016647821 abstract "Nasopharyngeal carcinoma is a unique cancer in the head and neck region. It has a very distinct geographic variation of incidence with more than ten times difference in incidence in high risk population compared with low-risk population. No other head and neck cancer has this large worldwide variation of incidence. It remained commonest cancer in young male adults below the age of 50 in southern China. The relative inaccessible anatomy and radiosensitivity has made radiotherapy the primary treatment in all stages of the cancer. The endemic form of the cancer is almost invariably associated with the Epstein Barr virus (EBV), making the EBV viral markers the first clinically applicable tumor marker in head and neck cancer. A large scale population study had demonstrated the feasibility to use EBV DNA titer to perform population screening for NPC in at risk population with survival benefits.1 The cure rate of NPC has markedly improved in the last 50 years. With modern combined modality treatment, stage Ⅲ disease can expect a 5-year survival of >70% and stage Ⅳ disease can expect a 5 year survival over 50%.2 This is mainly due to the improvement in radiotherapy technique and additional use of chemotherapy. Conventional two dimension radiotherapy used since the 1960's were unable to deliver high dose to tumors close to critical structures without damaging the critical structures due to radiation overdose. The late toxicities of conventional two-dimensional radiotherapy were also quite high. As many patients were young, survivors had significant long term deterioration of quality of life for many years.3 The introduction of intensity modulated radiotherapy (IMRT) had drastically changed the treatment of NPC. IMRT not just reduces the radiation toxicities to normal structures by spreading the radiation from 2 parallel beams to multiple beams of lower dosage, but also improves the contouring of radiation to the tumor and delivers adequate radiation dose to the tumor. With improved imaging and IMRT, tumor extension to oropharynx and nasal cavities can now be adequately treated and this is reflected in the 7th edition of UICC/AJCC cancer staging by downstaging oropharyngeal and nasal cavities extension from T2 to T1 disease. By sparing more adjacent organs from high dose radiation, IMRT also improves quality of life of the survivors, especially in regards to xerostomia,4 trismus and swallowing.5 IMRT relies on good radiation planning and high accuracy in delivering the intended radiation dosimetry to structures. As treatment continues, the size of the tumor and shape of the patient's body may change. In order to account for these changes, a strategy of re-planning during the course of the radiotherapy treatment has been proposed.6 The strategy is called adaptive radiotherapy. Adaptive radiotherapy can then compensate for the shift in the target tumor and critical structures as radiation treatment progress. This, unfortunately, would translate to extra manpower resource to re-plan the radiation treatment. Adaptive radiotherapy would probably be unnecessary in patients with small tumors and minimal weight loss during treatment. More clinical trials are required to define the patient subgroup that would benefit from adaptive radiotherapy and the most cost effective strategy to implement adaptive radiotherapy. Another technological advancement is the use of heavy ions like proton for delivery of radiation. The oretically intensity modulated proton therapy (IMPT) would be able to deliver a higher radiation dosage to the tumor volume while at the same time reducing the radiation dosage to organs at risk.7 This would be useful in advanced cancers where the tumor is close to the critical structure and also in re-irradiation setting where normal tissue already had significant exposure to prior radiation.8 An even newer radiation technique using heavy particles is the use of carbon ions for radiation. Initial reports showed even better toxicity sparing to critical structures than proton therapy for treatment recurrent nasopharyngeal carcinoma.9,10 These new technological advances would need larger scale clinical trials to define the role in management of nasopharyngeal carcinoma. The NPC 0099 trial has firmly established the value of adding chemotherapy to radiotherapy when treating nasopharyngeal carcinoma.11 With IMRT and concurrent cisplatin chemotherapy, local-regional failure of NPC after treatment is now less than 15%.12 The most common form for failure, however, is distant metastasis. It would be logical to added additional chemotherapy to reduce the incidence of distant metastasis more. However, clinical trial has not shown the benefit of additional adjuvant chemotherapy in patients already received high dose chemotherapy during the radiation treatment.13 Moreover, there is increased toxicities with additional high dose adjuvant chemotherapy to this group of patients. A new multi-center clinical trial from China published earlier this year, however, showed the benefit of neoadjuvant chemotherapy for advanced stage (stage Ⅲ – Ⅳb) NPC. The trial consisted of 480 patients randomly assigned to standard cisplatin based concurrent chemoradiation versus neoadjuvant chemotherapy with gemcitabine and cisplatin followed by standard chemoradiotherapy. The 3-year recurrence free survival improved from 76.5% to 85.3% when additional neoadjuvant chemotherapy was administered. Over 96% of the patient can complete all 3 courses of neoadjuvant chemotherapy.14 New target therapies and immunotherapies are coming out of research pipeline. However, when applied to NPC, most of the trails are still exploring the role of these novel therapies on metastatic diseases that failed conventional salvage treatment.15 However, these novel therapeutics, especially the immune checkpoint mediators may improve the efficacy of radiotherapy in the primary treatment setting. Also, as the mechanism of these novel therapeutics is different from chemotherapy and radiotherapy, the toxicity profile will be different. Addition of these novel therapeutics in the primary treatment setting may be more tolerable than higher dose of chemotherapy or radiotherapy. Still, large scale clinical trials will be needed to investigate the exact role of these novel therapeutics in the treatment of NPC. Due to the anatomical location of the nasopharynx and the radiosensitivity of endemic NPC, surgery has not been considered any role in primary treatment of NPC. For recurrent disease, because of the morbidities of additional radiation, surgery in the form of nasopharyngectomy, had been gaining attention for treating locally recurrent diseases. Before the 1980's, surgery on the nasopharynx for resection of malignant tumors had rarely been attempted. In the two decades of 1980–1990's, a variety of surgical approaches to the nasopharynx were described and larger surgical cohorts had shown survival benefits of salvage surgery for recurrent NPC.16 The disadvantages of all the traditional open approaches to nasopharynx are the morbidities related to transgressing a large amount of normal tissue in the head and neck area in order to expose the nasopharynx and perform the resection. This would lead to cosmetic and functional problems including facial scars, trismus and swallowing dysfunction. With advancement of technologies, minimally invasive surgery to the paranasal sinuses and anterior skull base can now be performed. Advancements in endoscopes, video systems and surgical tools, endoscopic surgery to the nasopharynx can now achieve comparable success in salvaging small locally recurrent NPC as with traditional open surgery, with much less morbidities. Endoscopic resection of rT1-2 recurrent NPC can achieve 3-year local control of 80%. Unfortunately, clinical trial comparing a surgical salvage versus non-surgical treatment would be very difficult to implement, partially to due to ethical issues and patients' preferences. We would still need to rely on high quality cohort studies and case-controlled studies to define the role of surgery versus other modalities of treatment in various scenarios of NPC.17 In the last 50 years, with the collaboration of scientists, medical physicists, engineers, radiation oncologists, medical oncologists and surgeon, there were significant improvement in all aspect of care in NPC patients. Not just survival has dramatically improved, complications from treatment have reduced and early detection screening programs can now be implemented in at risk population groups. While technologies would develop new and better machines and drugs, clinical trials are essential to define the exact benefit groups for these new and often expensive treatment modalities. Yet, the outlook is bright. There is no conflicts of interest." @default.
• W3016647821 created "2020-04-24" @default.
• W3016647821 creator A5026103070 @default.
• W3016647821 date "2020-03-01" @default.
• W3016647821 modified "2023-10-17" @default.
• W3016647821 title "Nasopharyngeal carcinoma – Improving cure with technology and clinical trials" @default.
• W3016647821 cites W1552166985 @default.
• W3016647821 cites W2011250897 @default.
• W3016647821 cites W2061616848 @default.
• W3016647821 cites W2071038583 @default.
• W3016647821 cites W2121916042 @default.
• W3016647821 cites W2125919881 @default.
• W3016647821 cites W2146900413 @default.
• W3016647821 cites W2149294014 @default.
• W3016647821 cites W2166243031 @default.
• W3016647821 cites W2214854399 @default.
• W3016647821 cites W2742681205 @default.
• W3016647821 cites W2747272999 @default.
• W3016647821 cites W2790813704 @default.
• W3016647821 cites W2947165726 @default.
• W3016647821 cites W2948576435 @default.
• W3016647821 cites W2964697239 @default.
• W3016647821 cites W2968210883 @default.
• W3016647821 doi "https://doi.org/10.1016/j.wjorl.2020.03.001" @default.
• W3016647821 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7221204" @default.
• W3016647821 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32426697" @default.
• W3016647821 hasPublicationYear "2020" @default.
• W3016647821 type Work @default.
• W3016647821 sameAs 3016647821 @default.
• W3016647821 citedByCount "3" @default.
• W3016647821 countsByYear W30166478212021 @default.
• W3016647821 countsByYear W30166478212022 @default.
• W3016647821 countsByYear W30166478212023 @default.
• W3016647821 crossrefType "journal-article" @default.
• W3016647821 hasAuthorship W3016647821A5026103070 @default.
• W3016647821 hasBestOaLocation W30166478211 @default.
• W3016647821 hasConcept C126322002 @default.
• W3016647821 hasConcept C143998085 @default.
• W3016647821 hasConcept C19527891 @default.
• W3016647821 hasConcept C2777546739 @default.
• W3016647821 hasConcept C2778997737 @default.
• W3016647821 hasConcept C509974204 @default.
• W3016647821 hasConcept C535046627 @default.
• W3016647821 hasConcept C71924100 @default.
• W3016647821 hasConceptScore W3016647821C126322002 @default.
• W3016647821 hasConceptScore W3016647821C143998085 @default.
• W3016647821 hasConceptScore W3016647821C19527891 @default.
• W3016647821 hasConceptScore W3016647821C2777546739 @default.
• W3016647821 hasConceptScore W3016647821C2778997737 @default.
• W3016647821 hasConceptScore W3016647821C509974204 @default.
• W3016647821 hasConceptScore W3016647821C535046627 @default.
• W3016647821 hasConceptScore W3016647821C71924100 @default.
• W3016647821 hasIssue "1" @default.
• W3016647821 hasLocation W30166478211 @default.
• W3016647821 hasLocation W30166478212 @default.
• W3016647821 hasLocation W30166478213 @default.
• W3016647821 hasLocation W30166478214 @default.
• W3016647821 hasLocation W30166478215 @default.
• W3016647821 hasOpenAccess W3016647821 @default.
• W3016647821 hasPrimaryLocation W30166478211 @default.
• W3016647821 hasRelatedWork W2014435840 @default.
• W3016647821 hasRelatedWork W2376480240 @default.
• W3016647821 hasRelatedWork W2791214854 @default.
• W3016647821 hasRelatedWork W2800549472 @default.
• W3016647821 hasRelatedWork W2910564439 @default.
• W3016647821 hasRelatedWork W3008905631 @default.
• W3016647821 hasRelatedWork W3143462561 @default.
• W3016647821 hasRelatedWork W4230673599 @default.
• W3016647821 hasRelatedWork W4291011330 @default.
• W3016647821 hasRelatedWork W4378449867 @default.
• W3016647821 hasVolume "6" @default.
• W3016647821 isParatext "false" @default.
• W3016647821 isRetracted "false" @default.
• W3016647821 magId "3016647821" @default.
• W3016647821 workType "article" @default.